RXRX Target Quotes Surge 10.53% Amid Bullish Fund Positioning

LayerZeroEnjoyer · 2025-12-31T15:22:37+00:00

Recursion Pharmaceuticals (RXRX) is seeing increased analyst attention, with price targets rising to an average of $7.14, suggesting significant upside potential. Institutional confidence remains strong despite slight declines in ownership count, with major investors like ARK increasing positions.

LayerZeroEnjoyer

2025-12-31 15:22:37

Abstract generation in progress

Recursion Pharmaceuticals (RXRX) is attracting renewed analyst attention, with consensus price targets climbing to $7.14 per share—a notable 10.53% bump from the prior guidance of $6.46 issued in early December 2025. The updated target quotes span a wide range, with projections stretching from $3.03 to $11.55, reflecting divergent views on the biotech firm’s trajectory. Against the current market price of $4.26 per share, the average target quotes suggest potential upside of approximately 67.61%.

Institutional Confidence on Display

The fund sentiment around RXRX reveals underlying strength. Some 505 funds and institutions maintain active positions, though this represents a slight 4.17% quarterly decline in institutional ownership count. More importantly, aggregate institutional holdings increased 4.20% to 378.3 million shares over the same period. Portfolio weighting among major funds averaged 0.18%, up 0.59% quarter-over-quarter—signaling renewed conviction. The put/call ratio of 0.24 underscores bullish sentiment in the options market.

Major Player Moves: ARK and Peers

ARK Investment Management remains the largest institutional holder with 33.5 million shares (6.52% stake), expanding its position by 1.66% sequentially. However, the firm trimmed its portfolio allocation weight by 20.38%, suggesting strategic rebalancing rather than reduced confidence. Baillie Gifford maintains a 4.66% stake (24 million shares) with a slight 0.81% reduction in holdings. Meanwhile, the ARK Innovation ETF (ARKK) increased its share count to 19.95 million (3.88% ownership)—a 6.50% gain—though similarly reducing relative portfolio allocation by 27.92%.

Long-term holders Softbank Group (14.7 million shares, 2.85%) and Kinnevik AB (13.4 million shares, 2.61%) showed no change in positions during the quarter, reflecting steady conviction.

What’s Next?

The convergence of rising target quotes, growing institutional ownership, and bullish options positioning paints an intriguing picture for RXRX investors seeking exposure to biotech innovation with institutional backing.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.